Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to new ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

“It's called GLP one receptor,” said Atul Malhotra, MD from the UC San Diego School of Medicine. It’s already FDA-approved to ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the European Congress on Obesity (ECO) in Malaga, Spain, reveal that the drug ...